What can we help you find?
Expert panelists consider the future of the treatment of multiple myeloma, with oral oncolytics being the standard of therapy.
Key opinion leaders discuss the iStopMM study and the importance of early screening.
The panelists discuss the collaborative care plan in place for providing patients with the optimal treatment of multiple myeloma.
Key opinion leaders expand upon the difficulties that arise from the oral oncolytic dispensary system, including the inadequacy of community centers, time-consuming documentation, the appropriate utilization contingencies, and more.
A discussion on the role of specialty pharmacies in the oral oncolytic distribution process and the difficulties of patients who are geographically challenged.
Peter Salgo, MD, et al., consider the dispensing capabilities of pharmacies in addition to 7-days-off treatment plans.
Key opinion leaders discuss the policy of prior authorization and how it may affect the timely delivery of oral oncolytic therapy.
The panel defines the REMS program and the criteria for obtaining authorization.
A discussion on the oral parity laws and their impact on costs.
Peter Salgo, MD, leads a discussion on the use of commercial co-pay cards to mitigate the financial burden of oral oncolytics.
Key opinion leaders compare Medicare Part B with Medicare Part D, and consider the effectiveness of Medicare Part D to offset the cost of oral oncolytic treatment.
Expert panelists review the available oral oncolytics and discuss how they compare with parental treatments.